Longitudinal natural history of type I spinal muscular atrophy: a critical review.
CHOP INTEND
Natural history
Spinal muscular atrophy
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
05 04 2020
05 04 2020
Historique:
received:
30
12
2019
accepted:
17
03
2020
entrez:
7
4
2020
pubmed:
7
4
2020
medline:
22
6
2021
Statut:
epublish
Résumé
The advent of new therapies in spinal muscular atrophy (SMA) has highlighted the need to have natural history data for comparison. Natural history studies using structured assessments in type I however are very limited. We identified and reviewed all the existing longitudinal history data in infants with type I SMA first assessed before the age of 7 months with the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND). Three longitudinal natural history studies, two performed in the United States and one in Italy, were identified. The different study design of these three studies made it possible for the cumulative dataset to include the full spectrum of severity; from infants with neonatal onset to those with a milder phenotype that were not always included in the individual natural history studies. The cumulative analysis confirmed that, even in a larger cohort, there was never an improvement on the CHOP INTEND over time. This was true for all the infants, irrespective of their age or baseline CHOP INTEND scores. Infants with neonatal onset had low CHOP INTEND scores and a fast decline. The relatively large number of patients allowed us to calculate the rate of progression in subgroups identified according to SMN2 copy number and baseline CHOP INTEND scores. A detailed understanding of the existing data is important, as it will be difficult to acquire new systematic longitudinal history data because of the availability of disease modifying therapies. The cumulative findings in this review help to better understand the variability of natural history data in untreated patients and will be of use for comparison to the real world patients treated with the recently approved therapies that have shown encouraging results in clinical trials.
Sections du résumé
BACKGROUND
The advent of new therapies in spinal muscular atrophy (SMA) has highlighted the need to have natural history data for comparison. Natural history studies using structured assessments in type I however are very limited. We identified and reviewed all the existing longitudinal history data in infants with type I SMA first assessed before the age of 7 months with the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND).
MAIN TEXT
Three longitudinal natural history studies, two performed in the United States and one in Italy, were identified. The different study design of these three studies made it possible for the cumulative dataset to include the full spectrum of severity; from infants with neonatal onset to those with a milder phenotype that were not always included in the individual natural history studies. The cumulative analysis confirmed that, even in a larger cohort, there was never an improvement on the CHOP INTEND over time. This was true for all the infants, irrespective of their age or baseline CHOP INTEND scores. Infants with neonatal onset had low CHOP INTEND scores and a fast decline. The relatively large number of patients allowed us to calculate the rate of progression in subgroups identified according to SMN2 copy number and baseline CHOP INTEND scores.
CONCLUSION
A detailed understanding of the existing data is important, as it will be difficult to acquire new systematic longitudinal history data because of the availability of disease modifying therapies. The cumulative findings in this review help to better understand the variability of natural history data in untreated patients and will be of use for comparison to the real world patients treated with the recently approved therapies that have shown encouraging results in clinical trials.
Identifiants
pubmed: 32248834
doi: 10.1186/s13023-020-01356-1
pii: 10.1186/s13023-020-01356-1
pmc: PMC7132885
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
84Références
Neuromuscul Disord. 2018 Feb;28(2):103-115
pubmed: 29290580
Neuromuscul Disord. 2018 Jan;28(1):24-28
pubmed: 29174525
Pediatrics. 2004 Nov;114(5):e548-53
pubmed: 15492357
Eur J Paediatr Neurol. 2018 Jan;22(1):122-127
pubmed: 29208343
J Child Neurol. 2011 Dec;26(12):1499-507
pubmed: 21940700
J Child Neurol. 2007 Aug;22(8):1027-49
pubmed: 17761659
N Engl J Med. 2017 Nov 2;377(18):1713-1722
pubmed: 29091557
N Engl J Med. 2017 Nov 2;377(18):1723-1732
pubmed: 29091570
Ann Clin Transl Neurol. 2016 Jan 21;3(2):132-45
pubmed: 26900585
Neurology. 2014 Aug 26;83(9):810-7
pubmed: 25080519
Folia Neuropathol. 2002;40(1):19-26
pubmed: 12121035
Neuromuscul Disord. 2010 Mar;20(3):155-61
pubmed: 20074952
Neuromuscul Disord. 2018 Jul;28(7):582-585
pubmed: 29960818
J Neuromuscul Dis. 2018;5(2):159-166
pubmed: 29865090
Lancet Neurol. 2017 Apr;16(4):264
pubmed: 28327335
Am J Phys Med Rehabil. 2007 May;86(5):349-55
pubmed: 17449979
Orphanet J Rare Dis. 2019 Jan 21;14(1):18
pubmed: 30665421
Neurology. 2018 Oct 2;91(14):e1312-e1318
pubmed: 30158155
Neuromuscul Disord. 2018 Mar;28(3):197-207
pubmed: 29305137
Ann Neurol. 2017 Dec;82(6):883-891
pubmed: 29149772
Neurology. 2016 Mar 8;86(10):890-7
pubmed: 26865511